Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 65%
filed 2026-06-18
Item 2.03
The filing discloses an increase in total commitments under a senior secured revolving credit facility from $4.100 billion to $4.138 billion ($38 million increase). While this represents a modification to an existing direct financial obligation under Item 2.03, it is a routine increase in an existing credit facility with no indication of covenant breach, distress, or material adverse change. The modest 0.93% increase and unchanged other terms suggest this is an administrative expansion rather than a material event triggering financial stress or restructuring concerns typical of the more specific event categories.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
Roku is filing an 8-K to reflect a material change in segment reporting structure, effective Q1 2026. The company reorganized from two segments (combined Platform) to three reportable segments (Advertising, Subscriptions, and Devices), requiring retrospective restatement of prior period financial information. While the filing explicitly states "This Form 8-K...is not an amendment to the 2025 Form 10-K or a restatement of the financial statements included therein," the retrospective application of segment changes to MD&A, Business, and Financial Statements sections is material to investors' understanding of the company's financial performance and structure. This does not fit cleanly into restatement (which typically involves accounting errors) but represents a significant organizational and reporting change that would affect investor analysis.
View raw filing on EDGAR →
8-K
Other material
confidence 73%
filed 2026-06-18
Item 1.01
Centrus Energy entered into a Seventh Amendment to its Section 382 Rights Agreement on June 18, 2026, extending the Final Expiration Date from June 30, 2026 to June 30, 2029 and increasing the purchase price for preferred stock. This tax-protection mechanism was approved by stockholders and is material to investors as it preserves the company's ability to utilize substantial NOL carryforwards under Section 382 of the Internal Revenue Code.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-18
Item 1.01
Honest Company entered into a material definitive lease agreement for approximately 38,240 square feet of corporate headquarters space in Playa Vista, California, with a 10-year initial term and total base rent obligation of approximately $33.4 million (net of rent abatement). This represents a significant capital commitment and strategic operational decision.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 7.01
NovoCure announced topline results from its Phase 3 TRIDENT trial, a pivotal clinical study evaluating TTFields therapy timing in glioblastoma treatment. The trial did not meet its primary endpoint of demonstrating statistically significant overall survival improvement for early initiation (HR 0.953; p=0.519), which is material to investors assessing the company's pipeline and commercial prospects. While this is clinical trial data rather than a traditional earnings release, the negative primary endpoint outcome for a Phase 3 pivotal trial is a material event affecting investor assessment of the registrant's development programs and future revenue potential.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-18
Item 2.03
This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) totaling approximately $5.85 billion across multiple tranches with trade dates of 6/15–6/16/2026. While Item 2.03 is nominally for "creation of a direct financial obligation," the filing itself notes that "consolidated obligations issuance is material to the Bank" and explicitly states no judgment has been made as to materiality of particular obligations. The disclosure is routine debt issuance reporting by a Federal Home Loan Bank, not a triggering covenant breach, going-concern issue, or other acute financial stress signal. The event is material to investors (substantial debt issuance affects capital structure and leverage), but does not fit neatly into more specific categories like covenant_breach or material_impairment; it is best classified as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-18
Item 2.02
The filing discloses a Board determination of net asset value (NAV) per share of $6.27 as of June 18, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). While NAV disclosure is material to investors in closed-end funds and similar investment vehicles, this does not constitute a traditional earnings release (which typically includes comprehensive financial results, revenue, net income, and forward guidance). The disclosure is a single valuation metric without accompanying financial statements or earnings data, making it distinct from the earnings_release category but clearly material to shareholders assessing the Company's value.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 3.03
The Board approved a 4-to-1 reverse stock split effective June 23, 2026, undertaken to satisfy Nasdaq's $1.00 minimum bid price requirement for continued listing. The reverse split modifies shareholder rights by reducing share count and changing the trading symbol and CUSIP.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-18
Item 7.01
The Board declared a quarterly dividend of $0.14 per share on Class I Common Stock, payable July 29, 2026, which is material to shareholders as it affects distributions and total return.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-18
Item 8.01
The Company disclosed its net asset value per share of $18.20 for Class I Common Stock as of May 31, 2026 and aggregate NAV of $1.7 billion as of June 17, 2026, along with a status update on its continuous private offering of unregistered shares totaling $2.5 billion in cumulative consideration.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 7.01
Alpha Metallurgical Resources disclosed significant damage to a critical stacker reclaimer machine at Dominion Terminal Associates (65% owned) caused by high winds on June 14, 2026, rendering the equipment inoperable and forcing the company to issue force majeure notices to customers and seek alternative shipping capacity.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
CMS recalculated the Company's Medicare Advantage Star Ratings upward for two contracts (H5141 from 3.5 to 4.5 Stars, H8010 from 4.0 to 4.5 Stars) following a court judgment in Clover Insurance Co. v. HHS. These rating improvements directly impact Quality Bonus Payments for payment year 2027, which are material to a Medicare Advantage insurer's revenue and competitive position. While this is favorable news, it does not fit neatly into the more specific event categories (it is neither an impairment, litigation settlement, nor operational change), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
GRI Bio announced FDA Orphan Drug Designation (ODD) for GRI-0621 in idiopathic pulmonary fibrosis, a significant regulatory milestone that provides potential seven-year U.S. market exclusivity, tax credits, and enhanced FDA engagement. While this is a material regulatory achievement for a clinical-stage biotech company, it does not fit neatly into the more specific event categories (it is not an earnings release, executive change, M&A activity, impairment, or litigation). The ODD is a positive regulatory catalyst that would affect investor assessment of the company's development pathway and long-term value creation.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 7.01
The disclosure announces that the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) status for NEO212, marking the first international regulatory clearance for the Company's lead clinical-stage drug candidate following Phase 1 completion. This represents a material regulatory milestone that advances the development pathway and expands the Company's clinical footprint internationally. While not a traditional earnings release, exec change, M&A activity, or other specifically enumerated event type, this regulatory approval is material to investors assessing the Company's clinical development progress and commercial prospects for a key asset.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-18
Item 1.01
Nuvve entered into a $1.5 million term loan agreement with ACH Capital West, LLC on June 12, 2026, with total repayment of $2.085 million due May 11, 2027, featuring aggressive weekly payments, substantial interest burden, and punitive default provisions that signal financial stress.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-18
Item 7.01
D-Wave announced a significant new product—its first gate-model quantum computing simulator with error-aware programming capabilities—along with new quantum development bundles launching in September 2026. This represents a material product milestone in the company's gate-model roadmap and introduces a new revenue-generating offering. While the disclosure does not fit neatly into the standard 8-K event categories (it is neither an earnings release, M&A activity, executive change, nor a financial restatement), the announcement of a differentiated, first-of-its-kind product with scheduled commercial availability and bundled pricing is material to investors assessing D-Wave's competitive position and near-term growth prospects.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
The Company disclosed monthly NAV per share as of May 31, 2026 for all share classes (Class S: $10.6218, Class N: $10.7109, Class D: $10.4819, Class I: $10.6982), along with a detailed breakdown of NAV components totaling $9.3 billion, portfolio update, and share repurchase activity of $143.8 million.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-18
Item 8.01
The filing discloses routine operational and financial metrics for the REIT as of May 31, 2026, including declared distributions per share class, NAV calculations, share repurchases, and portfolio composition.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
American Express issued €750 million of senior notes on June 17, 2026, a material debt issuance that affects the company's capital structure and financial obligations. While this is a routine debt offering disclosed under Item 8.01, it does not fit neatly into the more specific event categories (it is not M&A, not a covenant breach, not a restatement, etc.), making "other_material" the most appropriate classification for a significant financing event.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 1.01
Potomac Electric Power Company entered into a Bond Purchase Agreement on March 19, 2026, and issued $300 million in aggregate principal amount of First Mortgage Bonds across three series (5.00%, 5.30%, and 5.74%) on June 17, 2026. This material debt financing transaction affects the registrant's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
Brinker International issued a notice of redemption for all outstanding 8.250% Senior Notes due July 15, 2030, with redemption scheduled for July 15, 2026 at 104.125% of principal plus accrued interest. This is a material debt management event affecting the company's capital structure and liquidity, but does not fit neatly into the more specific taxonomy categories (not a covenant breach, not a restatement, not M&A activity). The redemption of a substantial debt obligation is material to investors assessing the registrant's financial position and cash flow.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
The IURC issued a Rate Order on June 17, 2026 approving a Stipulation and Settlement Agreement for AES Indiana's base rate case, establishing a $1,979.7 million revenue requirement, 9.5% return on common equity, and $5.5 billion rate base effective in two phases beginning July 2026. This is a material regulatory approval affecting the subsidiary's revenue and profitability, but does not fit neatly into the specific event categories (not earnings, M&A, impairment, litigation, or other defined types). The disclosure is material to investors as it directly impacts the registrant's financial performance and regulatory standing.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 8.01
Kforce entered into a Rule 10b5-1 stock trading plan on June 15, 2026 to repurchase its own common stock under a Board-authorized share repurchase program. While share buybacks are generally material corporate actions affecting capital allocation and shareholder value, this disclosure does not fit neatly into the more specific event categories (it is not a dilutive issuance, M&A activity, or executive compensation). The filing is material because it signals the Firm's intent to return capital and reflects management's confidence in the stock, but the event type is best classified as "other_material" given the absence of a dedicated taxonomy entry for routine buyback plan adoptions.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
ProtoKinetix formed a subsidiary (SightPath Biotech LLC) to develop PKX-001 for dry-eye disease with patents valued at approximately $253 million, disclosed late filings of its 2025 10-K and 2026 Q1 10-Q, and repriced 61.19 million options and 6 million warrants downward from $0.028 to $0.01 per share with extended expiration dates. The combination of subsidiary formation with substantial IP valuation, filing delays, and significant dilutive equity repricing reflects material corporate restructuring and financial stress.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
uniQure announced its plan to submit a BLA for AMT-130 in Huntington's Disease in Q3 2026, following FDA Type B meeting feedback that the 3-year Phase I/II data would be acceptable for accelerated approval. This is a material regulatory milestone for a gene therapy company, but does not fit neatly into the standard taxonomy categories (not an earnings release, executive change, M&A, impairment, or litigation). The disclosure is material to investors as it signals significant progress toward a potential regulatory approval pathway, though the event is contingent on future FDA alignment and BLA submission.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
Verastem announced positive updated results from the RAMP 205 Phase 1b/2a clinical trial evaluating avutometinib plus defactinib in combination with chemotherapy for metastatic pancreatic cancer, with an 86% overall survival rate at 6 months, 68% progression-free survival rate, and 52% objective response rate. The company also announced initiation of dosing in the TARGET-D 201 Phase 2 registration-directed trial for VS-7375.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 1.01
Enterprise Financial Services Corp completed a $175 million issuance of subordinated notes on June 17, 2026, pursuant to a registered offering under Form S-3, creating material direct financial obligations and expanding the company's capital structure.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 3.03
The registrant adopted a First Amended and Restated Certificate of Incorporation and Bylaws in connection with the business combination closing, materially modifying the rights of Class A stockholders.
View raw filing on EDGAR →
8-K
Other material
confidence 55%
filed 2026-06-17
Item 1.02
Plains GP Holdings terminated two material credit facilities (the Existing Revolving Credit Agreement and the Hedged Inventory Facility) and closed a new Revolving Credit Agreement, representing a routine refinancing of its credit arrangements.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
Southern Copper priced a $1.25 billion senior unsecured notes offering at 5.350% due 2036. While this is a material debt issuance that would affect investor assessment of the company's capital structure and financing activities, it does not fit cleanly into the more specific event categories (it is not a dilutive equity issuance, M&A activity, or other defined event type). The disclosure of a substantial debt offering under Item 8.01 warrants classification as a material event outside the standard taxonomy.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 1.02
South Plains Financial terminated a Board Representation Agreement with Henry TAW LP, a shareholder that originally owned approximately 16% and now owns less than 10% of outstanding shares. The termination reflects the Company's maturation as a public entity and shift toward a broader shareholder base.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
South Plains Financial entered into a stock repurchase agreement with retiring CEO Curtis C. Griffith to repurchase 300,000 shares at fair market value, approved by the board with Griffith recused. The repurchase is a related-party transaction tied to his retirement.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 2.03
CarMax entered into a $500 million term loan credit agreement with MUFG Bank on June 15, 2026, establishing a three-year term facility with customary covenants and interest terms.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 7.01
The disclosure announces completion of target enrollment in a Phase 2b clinical trial (MIST trial) for AP01, a lead product candidate. While this is a material clinical development milestone that would affect investor assessment of the company's pipeline progress and de-risking, it does not fit neatly into the standard taxonomy categories. The event is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated Item, and represents clinical trial progress rather than earnings, M&A, executive changes, or other specifically enumerated event types.
View raw filing on EDGAR →
8-K
Other material
confidence 35%
filed 2026-06-17
Item 8.01
The filing discloses a press release under Item 8.01 (Other Events) but provides no substantive detail about the content or nature of the announcement. Without access to Exhibit 99.1, the specific event cannot be determined. Given Verizon's size and the formal 8-K filing, the press release likely addresses a material matter, but the event type cannot be confidently classified without knowing its subject matter.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 5.03
Smartbird amended its Certificate of Incorporation and Bylaws to change the company name to Smartbird, Inc., remove public benefit corporation status, and lower the stockholder quorum requirement from a majority to one-third, representing material governance and structural changes.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 5.03
Allurion Technologies implemented a 1-for-15 reverse stock split, approved by stockholders at the December 2025 Annual Meeting, with the Charter Amendment filed on June 12, 2026 and effective June 17-18, 2026. This material corporate action affects the company's share structure, trading symbol, and terms of warrants and convertible securities.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 8.01
The Company resubmitted a New Drug Application (NDA) to the FDA for relacorilant, a treatment for Cushing's syndrome. This is a material regulatory milestone for a biopharmaceutical company, as NDA resubmission represents progress toward potential commercialization of a key product candidate. However, it does not fit neatly into the more specific event categories (e.g., it is not an earnings release, M&A activity, or executive change), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 1.01
The Company entered into a Third Amended and Restated Operating Agreement on June 15, 2026, which amended the operating agreement to reflect the liquidation and dissolution of Series I and updated indemnification provisions. This represents a material structural change to the Company's organizational documents and governance framework.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 5.03
Lakewood-Amedex Biotherapeutics approved and implemented a 1-for-10 reverse stock split, effective June 19, 2026, which was filed with the Nevada Secretary of State. This structural capital event materially modifies the rights of security holders by reducing share count and affecting trading mechanics and investor holdings.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 2.03
ISQ Open Infrastructure entered into a $60 million revolving credit facility (expandable to $180 million) on June 11, 2026, creating a direct financial obligation with customary covenants and events of default.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
Faraday Future announced a major product launch on June 16, 2026, including unveiling its "full-form EAI Robot World spanning six product series," launching a "Three-in-One EAI robotics education ecosystem strategy," and debuting an "All-New Futurist humanoid robot and FX Navi with pricing starting at $1,990." This represents a significant business development and product diversification announcement that would materially affect investor assessment of the company's strategic direction and revenue prospects, but does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, or other defined event type).
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 8.01
This Item 8.01 discloses the completion and post-closing mechanics of an IPO (20 million units at $10/unit generating $200M gross proceeds), a concurrent private placement ($2.1M), partial exercise of an over-allotment option (1.65M units, $16.5M), and placement of $216.5M in trust. While IPO completion is material, the disclosure is primarily administrative detail about capital raised and trust account mechanics rather than a discrete earnings release, M&A event, or other specific taxonomy event. The filing reports "as previously reported" events, suggesting this is a follow-up disclosure of already-announced transactions.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
The disclosure announces a 1-for-20 reverse share split effective July 1, 2026, for the 2x Long VIX Futures ETF (UVIX). While reverse splits are structural corporate actions that affect share price and outstanding share count, this event does not fit neatly into the delisting_risk category (no delisting threat is mentioned) nor any other specific taxonomy category. The action is material to shareholders as it affects NAV per share, share count, and potential tax consequences from fractional share redemptions, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Myseum.AI announced signing a non-binding letter of intent with Scanon.ai Systems to explore a collaborative development partnership involving integration of AI and computer vision capabilities into the Company's Picture Party platform, with potential reciprocal revenue sharing and participation in Scanon's financing round. While this represents a material strategic partnership announcement, it does not fit cleanly into the M&A taxonomy (no acquisition, merger, or change of control is disclosed—only a non-binding LOI for collaboration), nor does it constitute a standard earnings release, executive change, or other enumerated event type. The disclosure would affect a reasonable investor's assessment of the Company's strategic direction and product roadmap.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-06-17
Item 7.01
The Board unanimously approved submitting governance proposals to stockholders to eliminate the classified board structure and all supermajority voting provisions in the Articles of Incorporation. This represents a material change to corporate governance structure that would affect shareholder voting rights and director election processes. While not fitting neatly into the specific event categories (it is not a shareholder vote result, but rather a proposal for one), the elimination of classified boards and supermajority voting provisions is material to investors' assessment of governance and control dynamics.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 1.01
AXT's subsidiary Tongmei entered into a long-term supply agreement with Casela committing Casela to purchase approximately $25.4 million of InP wafer substrates during 2027, with 50% prepayment required within 15 business days. While this is a material commercial contract (Item 1.01), it is fundamentally a supply/customer agreement rather than a merger, acquisition, disposition, or change of control. The agreement secures significant committed revenue and prepayment but does not fit the specific M&A taxonomy categories, warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 8.01
The Company extended the expiration date of a rights offering from June 23 to June 29, 2026, at a subscription price of $6.90 per share. While this is a material capital-raising event affecting shareholder dilution and the Company's financing timeline, it does not fit neatly into the more specific categories (dilutive_issuance typically covers the initial announcement of an unregistered equity sale, not an extension of an existing offering). The extension itself is material to investors tracking the offering's progress and their subscription decision window.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-06-17
Item 7.01
The filing discloses a "strategic investment in Skyline Instruments Corporation" announced via press release on June 17, 2026. While the prose does not specify the investment amount, structure, or whether it constitutes a material acquisition under Item 1.01, a strategic investment by a public company is typically material to investors assessing the registrant's capital allocation and business strategy. The disclosure does not fit the more specific categories (ma_activity would require clearer language about acquisition/merger/change of control; dilutive_issuance would require equity issuance detail). Classified as other_material pending fuller details in the attached exhibit.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-06-17
Item 8.01
The disclosure announces a Board declaration of an annual cash dividend of $0.55 per share with specific payment and record dates. While dividend declarations are routine corporate actions, this is material to shareholders as it affects their investment returns and the company's capital allocation. However, it does not fit neatly into the more specific event categories (not earnings, not executive-related, not M&A, not a restatement or going-concern issue), so "other_material" is the most appropriate classification.
View raw filing on EDGAR →